-
Cannabinoid Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
10 Jul 2025 17:00 GMT
… Pharmaceuticals, InMed Pharmaceuticals, Corbus Pharmaceuticals, and others are evaluating new cannabinoid agonist drugs to … , Inc., Araclon Biotech S.L., Eisai Co., Ltd., TauRx Therapeutics, TrueBinding …
-
Five things for pharma marketers to know: Thursday, July 10, 2025
10 Jul 2025 10:54 GMT
… beyond Keytruda, Merck acquired Verona Pharma for about $10 billion. The … Eli Lilly’s Alzheimer’s drug, got FDA approval for an … an edge over Biogen and Eisai’s rival medication Leqembi. (Endpoints … for Lilly’s weight loss drug, Zepbound, blaming it and …
-
Eisai Pharma to establish GCC in Visakhapatnam
10 Jul 2025 04:59 GMT
… Global Chief Information Officer of Eisai Pharma, during his visit to … technologies, and pharmaceutical research with Eisai Pharma,” he stated.
Eisai’s visiting delegation … also included Eisai India …
-
Crohn's Disease Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight
10 Jul 2025 03:19 GMT
… 90+ companies and 90+ pipeline drugs in Crohn's Disease … Crohn's Disease pipeline drug profiles, including clinical and nonclinical … Therapeutics, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Fast Forward Pharmaceuticals, Suzhou Connect …
-
Japan to Cut Price of Alzheimer's Drug Lecanemab
10 Jul 2025 02:29 GMT
… Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and Biogen Inc … the official price of the drug by up to 15 pct … with conventional Alzheimer's drugs such as donepezil.
The margin …
-
FDA clears new, safer regimen for Lilly's Alzheimer's drug
09 Jul 2025 20:02 GMT
… -targeting therapies like Kisunla and Eisai/Biogen's rival … one reason why the two drugs have failed to gather much … blockbuster sales that accompanied both drugs as they went through clinical …
-
Lilly gets FDA OK of modified dosing for Alzheimer’s drug
09 Jul 2025 16:07 GMT
… Brief:
The Food and Drug Administration has approved a modified … Lilly’s Alzheimer’s disease drug Kisunla, permitting a smaller … physicians reluctant to prescribe the drug and resulted in its … ’s disease drugs on the market, along with Eisai and Biogen …
-
Lilly Gets FDA Label Update for Alzheimer’s Drug To Mitigate Safety Concerns
09 Jul 2025 13:08 GMT
… recommended monthly dose. The drug was approved in July 2024 … that have dogged the drug class since rival Eisai and Biogen received … , which showed that the drug removed amyloid plaques to minimal … market these new Alzheimer’s drugs. Despite being heralded as …
-
US FDA approves gradual dosing for Lilly Alzheimer’s drug
09 Jul 2025 11:22 GMT
… -The U.S. Food and Drug Administration approved changing the prescribing … Eli Lilly’s Alzheimer’s drug Kisunla to allow more gradual … part of a class of drugs designed to clear an …
Kisunla competes with Eisai and Biogen’s amyloid-lowering drug Leqembi, which …
-
Diffuse Large B-Cell Lymphoma Clinical Trails, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, And Pipeline Analysis Miltenyi Biomedicine, Adicet Bio, Velosbio, Novartis Pharmaceu
09 Jul 2025 01:44 GMT
… landscape. It covers the pipeline drug profiles, including clinical and nonclinical … , Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok …
About
© 1995-2025